News Press Releases

Alnylam to Host Third Annual "RNAi Roundtable" Webcast Series

ALNY | July 12, 2016

Alnylam to Host Third Annual "RNAi Roundtable" Webcast Series

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it plans to host its 3^rd Annual series of webcast "RNAi Roundtables" this summer and early fall. The 2016 series will consist of presentations from Alnylam scientists, clinical collaborators, and patients or patient advocates, who will review recent progress in many of the Company's development-stage pipeline programs. Each event will be webcast live on the Investors page of the Company's website, www.alnylam.com, and a replay of the roundtables will be posted on the Alnylam website approximately three hours after each event.

The first roundtable of the series will focus on patisiran and revusiran for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). This event will take place on Wednesday, July 20, 11:30 a.m. - 1:00 p.m. ET. Featured speakers include:

Eric Green, Vice President, General Manager, TTR Program
Jared Gollob, M.D., Vice President, Clinical Research
Guest Speaker: John L. Berk, M.D., Director, Clinical Trials for Familial Amyloidosis and Director, Localized Amyloid Clinic, Boston University Amyloidosis Center
Guest Speaker: Christina Lindsey, Patient living with hATTR amyloidosis

The second roundtable will focus on fitusiran for the treatment of hemophilia and rare bleeding disorders. This event will take place on Monday, August 22, 10:30 a.m. - 12:00 p.m. ET. Featured speakers include:

Akin Akinc, Ph.D., Vice President, General Manager, Fitusiran Program
Benny Sorensen, M.D., Ph.D., Medical Director, Clinical Development
Guest Speaker: Brian O’Mahony, Chief Executive, Irish Haemophilia Society Ltd. and person living with severe hemophilia B

Alnylam has scheduled additional RNAi Roundtables in the coming months focused on some of its other clinical programs, including: ALN-CC5 for the treatment of complement-mediated diseases, ALN-AS1 for the treatment of acute hepatic porphyrias, ALN-GO1 for the treatment of primary hyperoxaluria type 1 and ALN-HBV for the treatment of hepatitis B virus infection.

Additional details for the rest of the RNAi Roundtables, including speakers, dates and times will be provided on the Capella section of the Company's website, www.alnylam.com/capella.

About RNAi
RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, target the cause of diseases by potently silencing specific mRNAs, thereby preventing disease-causing proteins from being made. RNAi therapeutics have the potential to treat disease and help patients in a fundamentally new way.

About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam's pipeline of investigational RNAi therapeutics is focused in 3 Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases. In early 2015, Alnylam launched its "Alnylam 2020" guidance for the advancement and commercialization of RNAi therapeutics as a whole new class of innovative medicines. Specifically, by the end of 2020, Alnylam expects to achieve a company profile with 3 marketed products, 10 RNAi therapeutic clinical programs – including 4 in late stages of development – across its 3 STArs. The company's demonstrated commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Ionis, Novartis, Roche, Takeda, Merck, Monsanto, The Medicines Company, and Sanofi Genzyme. In addition, Alnylam holds an equity position in Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 200 peer-reviewed papers, including many in the world's top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, Cell, New England Journal of Medicine, and The Lancet. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information about Alnylam's pipeline of investigational RNAi therapeutics, please visit www.alnylam.com.